- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Talphera Inc.(TLPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TLPH
11/16/2026: TLPH (1-star) is currently NOT-A-BUY. Pass it for now.
Talphera Inc. is a micro-cap specialty pharmaceutical company transitioning from commercial pain management toward high-value institutional therapeutics. Its main pipeline strengths include Niyad, a lead nafamostat candidate with FDA Breakthrough Device Designation for regional anticoagulation in dialysis circuits. The primary investment story rests on advancing this clinical pipeline to capture significant unmet needs in hospital settings. Key risks involve clinical trial execution, binary regulatory outcomes, and minimal current product revenues. The stock best suits high-risk growth investors willing to monitor upcoming clinical data catalysts and regulatory milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential high-growth avenues if clinical pipeline catalysts succeed, though current revenues remain minimal. |
| Momentum investor | Strong fit while signal remains positive | Short-term momentum is heavily driven by clinical trial updates, regulatory news, and binary clinical data readouts. |
| Value investor | Weak fit | Traditional value metrics do not apply due to early-stage pre-commercial operations and ongoing net losses. |
| Dividend investor | Weak fit | The company pays no dividends and retains all capital to fund research and development. |
| Low-risk investor | Weak fit | High clinical trial dependency and micro-cap share volatility create a risk profile unsuitable for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap clinical-stage status makes the stock highly sensitive to market sentiment and news flow. |
| Valuation risk | High | Valuation is largely speculative, resting heavily on future regulatory approvals rather than current earnings. |
| Competition risk (standard care and renal therapies) | Medium / high | Talphera must successfully displace deeply entrenched legacy alternatives like heparin in hospital protocols. |
| Business quality | Medium | The business model relies on specialized high-value hospital therapeutics but currently lacks commercial-scale validation. |
| Dividend income | Low / none | No dividend is paid or anticipated in the near term. |
| Execution risk | High | Successful clinical trial execution and regulatory clearance are absolute prerequisites for corporate viability. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.07M USD | Price to earnings Ratio - | 1Y Target Price 3.12 |
Price to earnings Ratio - | 1Y Target Price 3.12 | ||
Volume (30-day avg) 137.9K shares | Beta 0.73 | 52 Weeks Range 0.69 - 1.57 | Updated Date 11/15/2026 |
52 Weeks Range 0.69 - 1.57 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 63.9%
- Active BUY / eligible
- 69 / 108
- 30-Day BUY Count Change
- +31
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 75.0%
- Active BUY / eligible
- 9 / 12
- 30-Day BUY Count Change
- +4
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 11.19% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Specialty Pharmaceutical Pipeline Licensing & Commercialization | Future product sales, commercial milestones, and licensing royalties derived from hospital-based therapeutics such as Niyad and partnered injectables. | Currently pre-revenue, the company is an investment in future product approvals rather than current sales. |
Valuation
Trailing PE - | Forward PE 1.02 | Enterprise Value 30.35M | Price to Sales(TTM) 47073.69 |
Enterprise Value 30.35M | Price to Sales(TTM) 47073.69 | ||
Enterprise Value to Revenue 30351 | Enterprise Value to EBITDA 0.11 | Shares Outstanding 51.96M | Shares Floating 25.55M |
Shares Outstanding 51.96M | Shares Floating 25.55M | ||
Percent Insiders 21.41 | Percent Institutions 45.82 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

